Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

including cancer cells that are no longer responsive to normal growth control mechanisms. Non- proliferating cells are relatively insensitive to Vidaza. Vidaza was approved for IV administration in January 2007.

About Epigenetics

Vidaza is the first of a new class of anti-cancer compounds known as epigenetic therapies. Epigenetics refers to changes in the regulation of gene expression, and DNA methylation and histone deacetylation are two of the more studied epigenetic regulators of gene expression. Epigenetic changes can silence gene expression and, unlike DNA mutations, may be reversed by targeting the mechanisms involved. The silencing of key cell cycle control genes and tumor suppressor genes through these two mechanisms of epigenetic regulation has been demonstrated in vitro and in vivo in hematological malignancies and in solid tumors. These key growth control genes can be re- expressed in cancer cells when DNA hypermethylation is reversed by Vidaza. The epigenetic approach to cancer therapy is that rather than using molecules that kill both normal, and tumor cells, the silenced genes are reactivated through targeted epigenetic therapy, re-establishing the cancer cell's natural mechanisms to control abnormal growth.

About MDS

Myelodysplastic syndromes, or MDS, are a group of diseases in which the bone marrow does not function normally, resulting in the production of malformed or immature blood cells. MDS affects approximately 40,000-50,000 people in the United States and 75,000-85,000 patients in Europe. The majority of patients with higher-risk MDS eventually experience bone marrow failure. Up to 50 percent of MDS patients succumb to complications, such as infection or bleeding, before progressing to acute myeloid leukemia (AML). MDS patients have a median survival of four months to five years depending on risk stratification. Higher-risk patients have a median survival of five to 14 months. Alleviation of disease-related complications
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  TNI BioTech, Inc. (OTCQB: ... focused on the development, marketing and distribution of ... definitive proxy materials with the Securities and Exchange ... of Shareholders to be held on Thursday, September ... The record date for determining those shareholders eligible ...
(Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
(Date:7/28/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 2014 financial results for the period ended June 30, 2014, ... will host a conference call and webcast that day at ... slide presentation relating to the call will be available via ... Call Details To access the live conference call via ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
(Date:7/28/2014)... July 28, 2014 Ticket Down ... Roma tickets in Dallas, TX at the Cotton Bowl. ... in the USA and it is an eight team tourney. ... the world including teams from La Liga, Serie A, English ... will battle it out on the pitch include: Manchester ...
(Date:7/28/2014)... Ticket Down is a dependable source ... FL at the Sun Life Stadium in early September. ... and Brazil has is one that has continues to go ... forming on a consistent basis. The rivalry between South ... the recent 2014 World Cup. To the delight of ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... dementia and heart rhythm irregularities are more likely to get ... In fact, the study of more than 16,000 people ... more likely to get a pacemaker than those without the ... is why folks with dementia are so much more likely ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
(Date:7/28/2014)... July 28, 2014 UT Southwestern Medical Center ... and irreversibly interferes with the activity of a ... tumors. , The molecule, SML-8-73-1 (SML), interferes with ... oncogene homolog. The gene produces proteins called K-Ras ... can result in normal cells dividing uncontrollably and ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2
... Online Science Writers Webinar , NCI and ASCO will ... Wide Web that will explore key issues surrounding cancer ... experts from the United States, Africa, Asia and India ... Incidence, Survival and Mortality Trends , The State ...
... planning proton treatments makes it possible to precisely ... distributed inside the patient,s body, PALO ALTO, Calif., ... has received FDA 510(k) clearance for a new proton,scanning ... beams are used to target tumors and other abnormalities. ...
... Reliable, Quick Patient-Information Retrieval From Multiple ... Ill., Dec. 14 AT&T Inc. (NYSE: ... Associates, Ltd. (JOHA) has,awarded AT&T a three-year ... addition to other network solutions. Continuing its ...
... AMSTERDAM, December 14 Kiadis Pharma announced ... for regulatory,classification as a "cell based" medicinal product ... the European Medicines Agency (EMEA). Based upon,this regulatory ... a,next step Kiadis Pharma will file for orphan ...
... Online Help for Living Longer, ... Stronger, KIRKLAND, ... odds of needing long term care,increase. One solution is long term care insurance ... Financial Partners,(LTCFP), "is the insurance plus health habits to keep yourself on your ...
... generation begins to join the ranks of the retired so ... consumers, says a new study funded by the Economic and ... media creations, it seems that the caricatures of silver surfers ... of older people increasingly mirror those of the rest of ...
Cached Medicine News:Health News:NCI/ASCO host science writers' seminar 2Health News:Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance 2Health News:Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance 3Health News:Local Joliet Physician Group Selects AT&T for Managed Online Data Solutions 2Health News:Local Joliet Physician Group Selects AT&T for Managed Online Data Solutions 3Health News:ATIR Classified as "Cell Based" Medicinal Product by the EMEA 2Health News:As More Americans Live to 100, Long Term Care Insurance Leader Gives Health Assist 2Health News:Retirees spending freely 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: